HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)

Subscribe to New Research on Vascular Endothelial Growth Factor Receptor-2

A 200-230-kDa tyrosine kinase receptor for vascular endothelial growth factors found primarily in endothelial and hematopoietic cells and their precursors. VEGFR-2 is important for vascular and hematopoietic development, and mediates almost all endothelial cell responses to VEGF.

Also Known As:

Vascular Endothelial Growth Factor Receptor 2; Fetal Liver Kinase-1; Flk-1 Protein; Flk-1 Receptor Tyrosine Kinase; KDR Tyrosine Kinase; Kinase Insert Domain Receptor; VEGF Receptor Flk-1; VEGF Receptor KDR; Fetal Liver Kinase 1; Flk 1 Protein; Flk 1 Receptor Tyrosine Kinase; Flk-1, VEGF Receptor; KDR, VEGF Receptor; Tyrosine Kinase, KDR; VEGF Receptor Flk 1; VEGFR-2

Networked: 1193 relevant articles (41 outcomes, 166 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hicklin, Daniel J: 26 articles (06/2009 - 04/2002)
2.	Zhu, Zhenping: 11 articles (09/2009 - 09/2004)
3.	Hicklin, D J: 10 articles (05/2006 - 05/2000)
4.	Bohlen, Peter: 10 articles (11/2005 - 06/2002)
5.	Alitalo, Kari: 9 articles (06/2015 - 10/2003)
6.	Myers, Jeffrey N: 8 articles (04/2011 - 04/2005)
7.	Kerbel, Robert S: 7 articles (12/2015 - 11/2004)
8.	Ylä-Herttuala, Seppo: 7 articles (06/2015 - 04/2002)
9.	Wei, Yu-Quan: 7 articles (05/2014 - 09/2003)
10.	Shibuya, Masabumi: 7 articles (01/2013 - 09/2003)

Related Diseases

1.	Neoplasms (Cancer) 09/01/2015 - "Novel anti-angiogenic treatments have been introduced in therapy to inhibit VEGFR-2 signaling; unfortunately, these drugs blocked tumor angiogenesis in pre-clinical murine models, but resulted far less effective in human patients. " 08/01/2004 - "Antiangiogenic treatment with a monoclonal antibody (mAb) directed against the vascular endothelial growth factor receptor-2 (VEGFR-2) is another promising treatment approach that can cause transient suppression of tumor growth. " 03/01/2007 - "These findings indicate that active immunization with rSFV particles coding for VEGFR-2 can break immunological tolerance and could potentially be used as part of a novel treatment for cancer." 11/01/2015 - "It binds to the angiogenesis marker vascular endothelial growth factor receptor 2 (VEGFR2) and has been studied in several preclinical and clinical phase I and II studies on tumor diagnostics and characterization. " 01/01/2013 - "Our study demonstrates VEGFR-2 as an essential molecule to sustain the "stemness" of GSLCs, their capacity to initiate tumor vasculature, and direct initiation of tumor."
2.	Melanoma (Melanoma, Malignant) 07/01/2013 - "Syngeneic human melanoma cell lines expressing either VEGFR-2 or NRP-1, both or none of them, were analyzed for their in vitro ability to migrate, invade the extracellular matrix (ECM) and secrete active metalloproteinase-2 (MMP-2). " 01/01/2012 - "CD8 T-cell induction against vascular endothelial growth factor receptor 2 by Salmonella for vaccination purposes against a murine melanoma." 12/15/2011 - "VEGFR-2 expression in human melanoma: revised assessment." 03/01/2011 - "RAF265, a novel B-Raf/vascular endothelial growth factor receptor-2 inhibitor, was evaluated in the preclinical setting for its ability to inhibit the uptake of PET tracers in the A375M(B-Raf(V600E)) human melanoma cell line. " 02/01/2005 - "Different VEGFR-2 immunostaining patterns were detected in the vast majority of melanomas (21/24; 88%). "
3.	Neoplasm Metastasis (Metastasis) 10/01/2013 - "Therefore, our data suggest that the expression of SHP2 in NSCLC has high specificity and sensitivity and is closely related to lymph node metastasis and the expression of VEGFR-2 and the MVD in patients with NSCLC. " 03/01/2008 - "A comparable decrease in lymphatic vessel density following blockade of VEGFR-2 (DC101) or the three VEGFRs (PTK/ZK) was observed in the metastases. " 09/01/2007 - "Low levels of VEGFR-2 were significantly associated with distant metastases. " 03/01/2007 - "Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice." 09/01/2006 - "[Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis]."
4.	Carcinoma (Carcinomatosis) 02/01/2011 - "This is the first study to elucidate the correlation between the expression of vasohibin in the stromal endothelial cells and the expression of VEGFR-2 in human cervical carcinomas." 05/01/2008 - "This is the first study to elucidate the correlation between expression of vasohibin in the stromal endothelial cells and that of VEGFR-2 in human carcinomas." 12/01/2014 - "Regarding VEGFR-2 expression, a small effect in carcinomas of both treated groups was found. " 11/01/2014 - "Vascular endothelial growth factor receptor 2, but not S100A4 or S100A6, correlates with prolonged survival in advanced urothelial carcinoma." 05/01/2013 - "VEGFR-2, CXCR-2 and PAR-1 germline polymorphisms as predictors of survival in pancreatic carcinoma."
5.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/15/2011 - "Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy." 07/01/2012 - "Our purpose was to evaluate VEGFR-2 polymorphisms as prognostic markers for tumor recurrence and overall survival (OS) in non-small-cell lung cancer (NSCLC). " 07/01/2012 - "Vascular endothelial growth factor receptor 2 gene polymorphisms as predictors for tumor recurrence and overall survival in non-small-cell lung cancer." 01/01/2013 - "Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor 2 (VEGFR2) have emerged as two effective clinical targets for non-small-cell lung cancer (NSCLC). " 10/01/2011 - "RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways."

Related Drugs and Biologics

1.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
2.	Protein-Tyrosine Kinases (Tyrosine Kinase)
3.	Phosphotransferases (Kinase)
4.	Epidermal Growth Factor Receptor (EGF Receptor)
5.	ramucirumab
6.	N- (4- bromo- 2- fluorophenyl)- 6- methoxy- 7- ((1- methylpiperidin- 4- yl)methoxy)quinazolin- 4- amine (ZD6474)
7.	Paclitaxel (Taxol)
8.	Vascular Endothelial Growth Factor Receptor-3 (Flt 4)
9.	AEE 788 (AEE788)
10.	glucuronyl glucosamine glycan sulfate (Vessel)

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
2.	Drug Therapy (Chemotherapy)
3.	Castration
4.	Immunotherapy
5.	Microbubbles